Synopsys, Inc. (NASDAQ:SNPS) Expected to Announce Earnings of $0.73 Per Share

Share on StockTwits

Equities analysts expect Synopsys, Inc. (NASDAQ:SNPS) to post earnings per share of $0.73 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Synopsys’ earnings. The highest EPS estimate is $0.77 and the lowest is $0.69. Synopsys reported earnings per share of $1.66 in the same quarter last year, which would suggest a negative year-over-year growth rate of 56%. The company is expected to announce its next earnings results on Wednesday, December 4th.

On average, analysts expect that Synopsys will report full-year earnings of $3.15 per share for the current year, with EPS estimates ranging from $3.11 to $3.19. For the next year, analysts forecast that the company will report earnings of $3.45 per share, with EPS estimates ranging from $3.23 to $3.57. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that follow Synopsys.

Synopsys (NASDAQ:SNPS) last posted its earnings results on Wednesday, August 21st. The semiconductor company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.03. The company had revenue of $853.00 million for the quarter, compared to analyst estimates of $831.03 million. Synopsys had a net margin of 18.94% and a return on equity of 16.56%. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $0.95 earnings per share.

Several equities research analysts have weighed in on the stock. Needham & Company LLC increased their target price on shares of Synopsys from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. BidaskClub lowered shares of Synopsys from a “buy” rating to a “hold” rating in a report on Wednesday, September 11th. KeyCorp increased their target price on shares of Synopsys from $152.00 to $153.00 and gave the stock an “overweight” rating in a report on Thursday, August 22nd. Credit Suisse Group reiterated a “positive” rating and issued a $150.00 target price (up from $125.00) on shares of Synopsys in a report on Thursday, August 22nd. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price (up from $150.00) on shares of Synopsys in a report on Thursday, August 22nd. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $143.10.

In related news, VP Sudhindra Kankanwadi sold 8,011 shares of the firm’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $144.30, for a total transaction of $1,155,987.30. Following the sale, the vice president now directly owns 8,663 shares in the company, valued at $1,250,070.90. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Steven Walske sold 2,453 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $126.54, for a total transaction of $310,402.62. Following the sale, the director now owns 14,038 shares in the company, valued at $1,776,368.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,881 shares of company stock worth $6,932,729. 1.84% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the stock. Next Capital Management LLC acquired a new stake in Synopsys in the 2nd quarter valued at $26,000. Hanseatic Management Services Inc. acquired a new stake in Synopsys in the 1st quarter valued at $30,000. Ruggie Capital Group acquired a new stake in Synopsys in the 2nd quarter valued at $32,000. Virtus ETF Advisers LLC acquired a new stake in Synopsys in the 2nd quarter valued at $34,000. Finally, Arcadia Investment Management Corp MI acquired a new stake in Synopsys in the 2nd quarter valued at $42,000. Institutional investors and hedge funds own 89.28% of the company’s stock.

SNPS opened at $133.21 on Tuesday. The firm’s fifty day moving average is $134.72 and its two-hundred day moving average is $124.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.90 and a current ratio of 0.99. The firm has a market cap of $20.23 billion, a PE ratio of 47.24, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23. Synopsys has a twelve month low of $79.14 and a twelve month high of $146.66.

Synopsys Company Profile

Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits (ICs). It offers Fusion Design Platform, a digital design implementation solution; Verification Continuum Platform, which provides virtual prototyping, static and formal verification, simulation, emulation, field-programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.

Read More: What is a portfolio manager?

Get a free copy of the Zacks research report on Synopsys (SNPS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synopsys (NASDAQ:SNPS)

Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report